294
Participants
Start Date
October 17, 2019
Primary Completion Date
October 31, 2026
Study Completion Date
October 31, 2027
Daratumumab SC in combination with Lenalidomide
"Daratumumab SC 1800 mg~* once every week for 8 weeks~* then once every other week for 16 weeks~* thereafter once every 4 weeks, until progression"
Lenalidomide PO (25mg)
Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression
Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
Hopital Haut-Leveque - Chu, Pessac
Chru Jean Minjoz, Besançon
Ch Blois Simone Veil, Blois
Ch Fleyriat, Bourg-en-Bresse
Chru Brest Site Hopital Morvan, Brest
Chu de Caen Normandie, Caen
Hopital Prive Sevigne - Cesson, Cesson-Sévigné
Chu Dijon Bourgogne, Dijon
Chu de Grenoble, Grenoble
Gpe Hospitalier La Rochelle-Re-Aunis, La Rochelle
Ch Chartres Louis Pasteur-Le Coudray, Le Coudray
Hôpital Claude Huriez, CHU, Lille
Institut Paoli Calmettes, Marseille
Chi Mont de Marsan Et Pays Des Sources, Mont-de-Marsan
Chu Montpellier, Montpellier
Chu de Nantes Site Hotel Dieu Hme, Nantes
Chu de Nice Hopital de L'Archet, Nice
Centre Hospitalier de Perigueux, Périgueux
Chru Rennes Site Pontchaillou, Rennes
Centre Hospitalier de Saint Quentin, Saint-Quentin
Centre Hospitalier Saint-Malo, St-Malo
Oncopole Chu Toulouse, Toulouse
Chu de Tours, Tours
University Hospital, Lille
OTHER